We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TFCFA
276
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $5.44M | 0.09% |
109,395
-16,687
| -13% | -$659K |
|
|
WBA
277
DELISTED
Walgreens Boots Alliance
WBA
| $5.42M | 0.09% |
90,217
+1,703
| +2% | +$110K |
|
|
RTN
278
DELISTED
Raytheon Company
RTN
| $5.31M | 0.08% |
27,472
-2,088
| -7% | -$439K |
|
279
Canadian National Railway
CNI
$78.3B
| $5.29M | 0.08% |
64,751
+3,636
| +6% | +$289K |
|
|
APLS
280
DELISTED
Apellis Pharmaceuticals
APLS
| $5.28M | 0.08% |
240,000
+116,000
| +94% | +$2.67M |
|
|
WRK
281
DELISTED
WestRock Company
WRK
| $5.27M | 0.08% |
92,498
+69,083
| +295% | +$4.24M |
|
282
PTC Therapeutics
PTCT
$6.37B
| $5.26M | 0.08% |
156,000
+34,000
| +28% | +$1.06M |
|
283
Agnico Eagle Mines
AEM
$72.6B
| $5.25M | 0.08% |
114,581
-114,705
| -50% | -$5.05M |
|
284
Air Products & Chemicals
APD
$66.3B
| $5.24M | 0.08% |
33,669
+8,425
| +33% | +$1.38M |
|
285
Kimberly-Clark
KMB
$36.4B
| $5.21M | 0.08% |
49,448
+15,497
| +46% | +$1.61M |
|
286
Prologis
PLD
$138B
| $5.19M | 0.08% |
78,945
+16,522
| +26% | +$1.06M |
|
|
287
FedEx
FDX
$74.5B
| $5.16M | 0.08% |
22,718
-66,035
| -74% | -$16.4M |
|
288
Lincoln National
LNC
$7.91B
| $5.16M | 0.08% |
82,801
-138,492
| -63% | -$9.48M |
|
|
RETA
289
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.13M | 0.08% |
146,700
+54,700
| +59% | +$1.67M |
|
290
CME Group
CME
$92.2B
| $5.13M | 0.08% |
31,280
+3,262
| +12% | +$533K |
|
291
Goodyear
GT
$2.07B
| $5.12M | 0.08% |
219,798
+187,500
| +581% | +$4.82M |
|
|
TIF
292
DELISTED
Tiffany & Co.
TIF
| $5.03M | 0.08% |
38,253
-36,849
| -49% | -$4.21M |
|
293
BCE
BCE
$19.9B
| $5.03M | 0.08% |
124,163
+30,368
| +32% | +$1.27M |
|
294
Corpay
CPAY
$24.2B
| $4.92M | 0.08% |
+23,335
| New | +$4.79M |
|
295
Labcorp
LH
$24.3B
| $4.91M | 0.08% |
31,826
-18
| -0.1% | -$2.72K |
|
296
Aflac
AFL
$63.9B
| $4.88M | 0.08% |
113,366
+6,896
| +6% | +$310K |
|
297
Scotiabank
BNS
$106B
| $4.73M | 0.07% |
83,552
+3,621
| +5% | +$218K |
|
298
Oneok
OKE
$58.7B
| $4.72M | 0.07% |
67,582
+3,795
| +6% | +$244K |
|
|
XLRN
299
DELISTED
Acceleron Pharma
XLRN
| $4.71M | 0.07% |
97,000
+37,000
| +62% | +$1.35M |
|
|
RVNC
300
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.69M | 0.07% |
171,000
| – | – |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.